Promising Clinical Efficacy and Toxicity Profile of Isatuximab Based Regimens for Treatment of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Systematic Review

Conclusion:In RRMM pts, ISA as a single agent has shown weaker efficacy when compared to combination regimens i.e. ORR 21% vs. 58%. The best result was seen when ISA was used in combination with CFZ demonstrating an ORR of 80%. In NDMM pts, combination regimens have shown excellent efficacy with an ORR of 87%. Nausea and fatigue were the major AEs reported with the monotherapy while neutropenia, leucopenia, and lymphopenia were the major AEs reported with the combination regimens. Further studies involving a larger population are required to gather evidence in favor of the improved efficacy and to evaluate AEs.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Shah, Z., Shafqat, M., Jamil, F., Malik, M. N., Rafae, A., Aslam, S., Qureshi, A., Sadiq, M., Abu Zar, M., Kamal, A., Selene, I. I., Samuel, S., Riaz, R., Lakhani, M., Anwer, F. Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster I Source Type: research